ABSTRACT
We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000-2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35-76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10-15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17-3.35] per 10-year increment, P = 0.011).
Subject(s)
Central Nervous System Infections/virology , Herpes Zoster/virology , Herpesvirus 3, Human/physiology , Acyclovir/therapeutic use , Adult , Aged , Antiviral Agents/therapeutic use , Central Nervous System Infections/drug therapy , Central Nervous System Infections/immunology , Female , Herpes Zoster/drug therapy , Herpes Zoster/immunology , Herpesvirus 3, Human/genetics , Herpesvirus 3, Human/isolation & purification , Humans , Immunocompromised Host , Male , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND: Influenza vaccination coverage is low in France, in at-risk patients and in healthcare workers. AIM: We aimed to estimate the incidence of nosocomial influenza, its characteristics and outcome. METHODS: During one influenza season, we retrospectively evaluated all cases of documented influenza. Inpatients with symptoms onset ≥48 h after admission were enrolled. Data were collected on a standardized questionnaire. RESULTS: From November 2017 to April 2018, 860 patients tested positive for influenza by polymerase chain reaction analysis on a respiratory sample. Among them, 204 (23.7%) were diagnosed ≥48 h after admission, of whom 57 (6.6% of all influenza cases) fulfilled inclusion criteria for nosocomial influenza: 26 women and 31 men, median age 82 years (interquartile range, 72.2-86.9). Twenty patients (38.6%) had recently (<6 months) received the seasonal influenza vaccine. Median time between admission and symptoms onset, and between symptoms onset and diagnosis were, respectively, 11 days (7-19.5) and 29 h (15.5-48). Influenza was mostly acquired in a double-bedded room (N = 39, 68.4%), with documented exposure in 14 cases. Influenza B virus was more common in nosocomial (46/57, 80.7%), than in community-acquired cases (359/803, 44.6%), P<0.001. Mortality rate at three months was 15.8% (N = 9). Incidence of nosocomial influenza was estimated at 0.22 per 1000 hospital-days during the study period. CONCLUSION: Nosocomial influenza is not rare in elderly inpatients, and may have severe consequences. Influenza B virus was over-represented, which suggests higher transmissibility and/or transmission clusters.
Subject(s)
Cross Infection/epidemiology , Influenza Vaccines/administration & dosage , Influenza, Human/epidemiology , Vaccination Coverage/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cross Infection/virology , Female , France/epidemiology , Health Personnel/statistics & numerical data , Hospitalization/statistics & numerical data , Humans , Incidence , Influenza, Human/prevention & control , Male , Middle Aged , Retrospective Studies , Young AdultSubject(s)
Confusion/etiology , Encephalitis, Varicella Zoster/diagnosis , Meningoencephalitis/diagnosis , Acute Kidney Injury/chemically induced , Acyclovir/adverse effects , Acyclovir/therapeutic use , Aged , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , DNA, Viral/cerebrospinal fluid , Diagnosis, Differential , Encephalitis/diagnosis , Encephalitis, Varicella Zoster/cerebrospinal fluid , Encephalitis, Varicella Zoster/diagnostic imaging , Exanthema/etiology , Hashimoto Disease/diagnosis , Herpes Zoster Ophthalmicus/complications , Herpes Zoster Ophthalmicus/drug therapy , Herpesvirus 3, Human/immunology , Herpesvirus 3, Human/isolation & purification , Humans , Magnetic Resonance Imaging , Male , Meningoencephalitis/cerebrospinal fluid , Meningoencephalitis/diagnostic imaging , Meningoencephalitis/virology , Neuroimaging , RecurrenceABSTRACT
Aseptic meningitis is defined as meningeal inflammation - i.e. cerebrospinal fluid (CSF) pleocytosis≥5 cells/mm3 - not related to an infectious process. Etiologies of aseptic meningitis can be classified in three main groups: (i) systemic diseases with meningeal involvement, which include sarcoidosis, Behçet's disease, Sjögren's syndrome, systemic lupus erythematosus and granulomatosis with polyangiitis; (ii) drug-induced aseptic meningitis, mostly reported with non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics (sulfamides, penicillins), intravenous immunoglobulin, and monoclonal antibodies; (iii) neoplastic meningitis, either related to solid cancer metastasis (breast cancer, lung cancer, melanoma) or malignant hemopathy (lymphoma, leukemia). Most series in the literature included groups of meningitis that are not stricto sensu aseptic, but should rather be included in the differential diagnosis: (i) infectious meningitis related to virus, parasites, fungi, or fastidious bacteria that require specific diagnostic investigations; (ii) bacterial meningitis with sterile CSF due to previous antibiotic administration, and (iii) parameningeal infections associated with meningeal reaction. Despite progress in microbiological diagnosis (including PCR, and next generation sequencing), and identification of a growing panel of autoimmune or paraneoplastic neurological syndromes, up to two thirds of aseptic meningitis cases are of unknown etiology, finally labeled as 'idiopathic'. Description of new entities, such as the syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL) may decrease the proportion of idiopathic aseptic meningitis. This state-of-the-art review summarizes the characteristics of main causes of aseptic meningitis.
